STOK - CIK 0001623526
The table below shows Stoke Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $45.59M | -$86.85M | -$81.07M | -$31.87M | -$66.91M | -$42.22M |
| Capital expenditure | $670.00K | $203.00K | $1.62M | $3.96M | $1.20M | $1.05M |
| Investing cash flow | -$186.81M | -$107.47M | $105.95M | -$45.88M | -$76.43M | -$1.05M |
| Dividends paid | - | - | - | - | - |
Stoke Therapeutics, Inc. reported operating cash flow of $45.59M for fiscal year 2025. That is up 152.5% from -$86.85M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$10.96M (FY 2018) to $45.59M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $97.39M | $131.09M | $53.01M | $46.41M | $1.28M | $108.11M |